ScreenerHero

CADL Candel Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · candeltx.com
9.820USD-0.51%Mkt Cap: 751.41M $P/E: —

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Ph…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap751.41M USD
Enterprise Value603.19M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-38.18M USD
Revenue/Share—
Last Price9.820 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees55
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-15.79
PEG—
EV/EBITDA-8.46
EV/Revenue—
P/S—
P/B5.96
EPS (TTM)-1.46
EPS (Forward)-0.63
52W Range
4.35058% of range13.85
52W High13.85 USD
52W Low4.350 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-73.54%
ROA-30.50%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-38.31M USD
CapEx (TTM)587.00K USD
FCF Margin—
FCF Yield-4.76%
Net Debt-152.05M USD
Net Debt/EBITDA2.13
Balance Sheet
Debt/Equity0.94
Current Ratio16.09
Quick Ratio15.89
Book Value/Sh1.66 USD
Cash/Share2.63 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)21.75 USD
Upside (mean)+121.5%
Target Range15.00 USD – 29.00 USD
15.00+121.5% to mean29.00
# Analysts8
Ownership
Shares Out.76.52M
Float60.22M
Insiders14.65%
Institutions67.65%
Short Interest
Short Ratio9.6d
Short % Float20.74%
Short % Out.16.13%
Shares Short12.34M
Short (prev mo.)12.46M
Technical
SMA 5011.46 (-14.3%)
SMA 2007.988 (+22.9%)
Beta-0.31
S&P 52W Chg16.45%
Avg Vol (30d)1.22M
Avg Vol (10d)973.87K
Technical Indicators
RSI (14)36.2
MACD-0.3951
MACD Signal-0.2109
MACD Hist.-0.1843
BB Upper12.44 USD
BB Middle10.95 USD
BB Lower9.463 USD
BB Width27.15%
ATR (14)0.6663 USD
Vol Ratio (20d)0.54x